Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. The obesity data keeps coming this week. We’ll get straight into it.
The need-to-know this morning
- Rezolute said its experimental drug failed to reduce episodes of low blood sugar in patients with congenital hyperinsulinism, missing the efficacy goal of a Phase 3 trial.
- AC Immune said its immunotherapy showed the potential to slow the progression of Parkinson’s disease, based on preliminary results from a mid-stage study.
- Rhythm Pharma announced preliminary study data showing its drug could reduce hunger cravings and lower the BMI of people with Prader-Willi Syndrome.
- Geron announced a corporate restructuring, including a one-third reduction in its workforce.
Lilly’s triple-G drug leads to major weight loss, but with many discontinuations
Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, but rates of side effects were high and many participants discontinued the treatment, including people who felt they were losing too much weight.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply